Wednesday, November 16, 2016
- 11:00AM-12:30PM
-
Abstract Number: 3201
Diagnostic Value of Quantitative Sialoscintigraphy Compared to Labial Salivary Gland Biopsy in Patients with Suspected SjöGren’ Syndrome
Imaging of Rheumatic Diseases III: Crystal Arthritis, Osteoarthritis, Connective Tissue Disease and Vasculitis- 11:00AM-12:30PM
-
Abstract Number: 3220
Distinct Single Cell Gene Expression Signatures of Monocyte Subsets Differentiate Between TNF-Alpha Inhibitor Treatment Response Groups in Rheumatoid Arthritis
Rheumatoid Arthritis – Human Etiology and Pathogenesis II- 11:00AM-12:30PM
-
Abstract Number: 3225
Dual Cytokine Inhibition with ABT-122, a Tnf– and IL-17–Targeted Dual Variable Domain Immunoglobulin (DVD-Ig™): Results from a 24-Week Open-Label Extension Study in Patients with Rheumatoid Arthritis
Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy V: New Biologics and Remission Induction- 11:00AM-12:30PM
-
Abstract Number: 3211
Early Radiological Progression in Rheumatoid Arthritis Leads to More Long-Term Joint Damage in Daily Clinical Practice; Six Year Radiological Outcomes of a Strict Treat-to-Target Cohort in the Netherlands
Rheumatoid Arthritis – Clinical Aspects VII: The Impact of Treating to Target- 11:00AM-12:30PM
-
Abstract Number: 3206
Effectiveness of Childhood Vaccinations in CAPS Patients Treated with Canakinumab: Results from an Open-Label Phase III Extension Study
Pediatric Rheumatology – Clinical and Therapeutic Aspects III: Autoinflammatory Diseases and Juvenile Dermatomyositis- 11:00AM-12:30PM
-
Abstract Number: 3205
Efficacy and Safety of Canakinumab in Patients with Periodic Fever Syndromes (Colchicine-Resistant FMF, HIDS/MKD AND TRAPS): Results from a Phase 3, Pivotal, Umbrella Trial
Pediatric Rheumatology – Clinical and Therapeutic Aspects III: Autoinflammatory Diseases and Juvenile Dermatomyositis- 11:00AM-12:30PM
-
Abstract Number: 3222
Efficacy and Safety of Monotherapy with Sirukumab, an Anti–IL-6 Cytokine Monoclonal Antibody, Compared with Adalimumab Monotherapy in Biologic-Naive Patients with Active Rheumatoid Arthritis: Results of a Global, Randomized, Double-Blind, Parallel-Group, Phase 3 Study
Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy V: New Biologics and Remission Induction- 11:00AM-12:30PM
-
Abstract Number: 3221
Efficacy and Safety of Sarilumab Versus Adalimumab in a Phase 3, Randomized, Double-Blind, Monotherapy Study in Patients with Active Rheumatoid Arthritis with Intolerance or Inadequate Response to Methotrexate
Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy V: New Biologics and Remission Induction- 11:00AM-12:30PM
-
Abstract Number: 3223
Efficacy and Safety of Sirukumab, an Anti–IL-6 Cytokine Monoclonal Antibody, in Patients with Active Rheumatoid Arthritis Despite Anti-TNF Therapy: Results from a Randomized, Double-Blind, Placebo-Controlled, Global, Phase 3 Study
Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy V: New Biologics and Remission Induction- 11:00AM-12:30PM
-
Abstract Number: 3248
Efficacy of Mycophenolate Mofetil and Oral Cyclophosphamide on Skin Thickness: Post-Hoc Analyses from the Scleroderma Lung Study I and II
Systemic Sclerosis, Fibrosing Syndromes, and Raynaud's – Clinical Aspects and Therapeutics III- 11:00AM-12:30PM
-
Abstract Number: 3224
Efficacy of Sirukumab, an Anti–IL-6 Cytokine Monoclonal Antibody, Based upon Prior Use of Non-Anti-TNF Biologics in Patients with Active Rheumatoid Arthritis Despite Anti-TNF Therapy: Results from a Global Phase 3 Study
Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy V: New Biologics and Remission Induction- 11:00AM-12:30PM
-
Abstract Number: 3190
Epidemiology of Polymyalgia Rheumatica 2000-2014: A Population Based Study
Epidemiology and Public Health III: Psoriatic Arthritis and More- 11:00AM-12:30PM
-
Abstract Number: 3239
Expression of IFN-Regulated Genes in Autoantibody Exposed Babies in Utero